研

Search documents
申万宏源(000166) - 000166申万宏源投资者关系管理信息20250709
2025-07-09 11:48
1 证券代码:000166 证券简称:申万宏源 申万宏源集团股份有限公司投资者关系活动记录表 编号:2025-0709 | 投资者关系活动 | √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他 | | 参与单位名称及 | 国金证券分析师及投资者 | | 人员姓名 | | | 时 间 | 2025 年 7 月 9 日 16:00-17:00 | | 地 点 | 公司会议室 | | 上市公司接待人 | 李 丹、王可昕,申万宏源集团股份有限公司董事会办公室/ | | 员姓名 | 战略管理部人员 | | 1. | 请介绍公司投行业务开展情况 | | | 公司坚持以客户为中心,强化"研究+投资+投行"联动, | | | 持续加强 IPO、再融资项目储备,加快巩固业务优势,第一 | | | 季度投行业务迎来开门红,实现投资银行手续费净收入 3.07 | | | 亿元,同比增长 79.40%,公司完成股权融资项目家数排名行 | | 投资者关系活动 主要内容介绍 | 业第 5,债券承销业务规模排名行业第 ...
一个月4.6倍涨幅或还不是北海康成-B(01228)的终点?
智通财经网· 2025-07-09 11:46
7月9日,北海康成-B(01228)股价在开盘后便迅速拉高,半小时后涨幅便超过50%,上午11时左右,其股价触及0.85港元,涨幅达到60.38%,北海康成也由此 走出"三连阳"。此前7月7日和8日,北海康成分别收涨24.64%和23.26%。也就是说,其三个交易日内股价最大涨幅便达到165.63%。 北海康成的这一涨幅也印证了智通财经APP此前对该股的判断。 今年6月18日,智通财经APP在《智通特供|股价拉升2.5倍成交量创上市新高,北海康成-B(01228)吹响估值反攻号角?》一文中指出"北海康成二级市场股价快 速拉升,侧面反映出投资者对其后续创新价值释放和重磅BD达成的乐观态度。从估值情况来看,即便公司股价短期拉升超2.5倍,其PS估值也仅有1.76倍, 远低于行业平均7.66倍,依然存在极大的股价和估值增长空间。" 在出现连续的下跌行情后,6月30日当天,北海康成股票成交量仅剩200.2万股,场内惜筹情绪基本达到极致,对应场外持币者抢筹情绪开始高涨。7月2日至 7月8日,北海康成在股价持续拉升的同时,股票成交量开始逐日递增,分别为240.80万股、728.10万股、906.50万股、1515.10万 ...
主流合资车企回暖态势强劲 上半年销量最高增幅16%
Mei Ri Jing Ji Xin Wen· 2025-07-09 11:16
Core Viewpoint - The mainstream joint venture automakers have shown a strong recovery in sales during the first half of the year, with notable growth in companies like FAW Toyota and SAIC Volkswagen, driven by the effectiveness of their "oil-electric integration" strategy [1][2]. Sales Performance - FAW Toyota sold 377,800 vehicles, a year-on-year increase of 16% - FAW-Volkswagen sold 436,100 vehicles, up 3.5% year-on-year - SAIC Volkswagen's sales reached 523,000 vehicles, a 2.3% increase - SAIC General sold 245,100 vehicles, marking an 8.64% growth - GAC Toyota achieved a total sales of 364,200 vehicles, showing positive growth [2]. Strategic Initiatives - The "oil-electric integration" strategy has helped stabilize the core market for fuel vehicles while accelerating the launch of competitive electric products [2][5]. - FAW-Volkswagen has implemented a three-step intelligent driving roadmap for fuel vehicles, aiming to enhance their competitiveness [3]. - GAC Toyota's flagship fuel vehicles, including Camry and Highlander, saw a total sales increase of 30% in the first half of the year [3]. Localization and R&D - Joint venture automakers are shifting their strategies from global technology import to local market dominance, with a focus on localized R&D [5][6]. - FAW Toyota's "RCE system" allows for localized decision-making and development, resulting in strong demand for the bZ5 electric model [5]. - Volkswagen aims to enhance its R&D capabilities in China, planning to launch over 11 new models by 2026 [6]. Marketing Strategies - The "one-price" marketing strategy has been widely adopted among joint venture automakers, enhancing sales through price transparency and significant discounts [8][9]. - This strategy simplifies the purchasing process and directly competes with new energy vehicle brands by offering substantial price reductions [9][10]. - The shift to a "one-price" model has improved consumer experience by eliminating uncertainties in pricing and enhancing service quality from dealers [10].
闻泰科技: 众华会计师事务所(特殊普通合伙)关于上海证券交易所《关于闻泰科技股份有限公司2024年年度报告的信息披露监管问询函》有关财务问题回复的专项说明
Zheng Quan Zhi Xing· 2025-07-09 11:13
众会字(2025)第 08929 号 关于上海证券交易所 《关于闻泰科技股份有限公司 2024 年年度报告的信 息披露监管问询函》 有关财务问题回复的专项说明 关于上海证券交易所 《关于闻泰科技股份有限公司 2024 年年度报告的信息披露监管 问询函》有关财务问题回复的专项说明 上海证券交易所: 于 2024 年末,公司承担的有息负债及本年内相应承担的利息支出如下: 我们接受委托,审计了闻泰科技股份有限公司(以下简称"闻泰科技"或"公 司")2024 年的年度财务报表,包括 2024 年 12 月 31 日的合并及公司资产负债 表,2024 年度的合并及公司利润表、合并及公司现金流量表、合并及公司所有者 权益变动表以及财务报表附注,并出具了众会字(2025)第 04980 号审计报告。 贵所于 2025 年 5 月 23 日收到上海证券交易所《关于闻泰科技股份有限公司 师根据问询函的要求对问询函提出的相关问题进行了核查,回复如下: 问题一:年报及前期公告显示,2024 年末公司货币资金、交易性金融资产 账面余额分别为 78.34 亿元、17.63 亿元,合计金额 95.97 亿元,同比增长 存放于境外款项 2 ...
Meta Platforms(META.O):在英国剑桥新建价值1600万美元的音频研究实验室。
news flash· 2025-07-09 11:08
Meta Platforms(META.O):在英国剑桥新建价值1600万美元的音频研究实验室。 ...
神州细胞收盘下跌2.74%,滚动市盈率337.77倍,总市值342.91亿元
Jin Rong Jie· 2025-07-09 11:03
从行业市盈率排名来看,公司所处的生物制品行业市盈率平均74.16倍,行业中值44.75倍,神州细胞排 名第73位。 截至2025年一季报,共有13家机构持仓神州细胞,其中其他7家、基金6家,合计持股数33127.91万股, 持股市值134.96亿元。 7月9日,神州细胞今日收盘77.0元,下跌2.74%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到337.77倍,总市值342.91亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13神州细胞337.77306.30-84.73342.91亿行业平均 74.1659.3810.22203.06亿行业中值44.7540.852.9483.84亿1西藏药业11.7911.302.90118.84亿2长春高新 18.8516.031.76414.10亿3川宁生物20.1319.213.28268.95亿4安科生物20.9820.723.59146.51亿5英诺特 21.0416.712.0041.25亿6上海莱士22.9420.941.41459.35亿7派林生物23.7322.682.11169.08亿8华兰生物 25.3326.532 ...
Listen Labs:把用户研究“黑灯流水线”化,AI Agent 系统实现小时级洞察
海外独角兽· 2025-07-09 10:50
作者:Hongyu 编辑:penny Listen Labs 由两位哈佛校友 Florian Juengermann 与 Alfred Wahlforss 在 2024 年底联合创立,并在 2025 年 4 月连获 Sequoia 领投的种子轮与 A 轮合计 2700 万美元融资,目标是打造一套能 自动招募受访者、主持上千场多语访谈、即时归档并复用洞察 的"AI 用户研究员"体系。 今年 2–5 月,Listen Labs 依次发布三项核心能力:1) AI Interviewer 可同时主持上千场语音/视频深访并动态追问;2) Insight Engine 把转录、情绪与行为 数据送入 GPT-4o 管线,几分钟生成主题聚类与可下载 PPT;3) Research Warehouse 将所有历史项目向量化存档,研究者可像 ChatGPT 一样对话检索并触 发"一键再访谈"。 在 AI 赋能用户研究的两条主线中,一条是传统无主持可用性测试借助 LLM 做摘要与打标签;另一条则是 Listen Labs 所聚焦的 全流程自动化深访 ——让 AI 主持人+ 用户访谈池(panel network)把"招募-访谈-分 ...
“京彩夏日”来袭!五大板块万余场文旅活动诚邀游客畅游北京
Bei Jing Ri Bao Ke Hu Duan· 2025-07-09 09:26
Group 1: Core Activities and Offerings - Beijing's cultural and tourism bureau has launched the "Jingcai Summer" series of activities, featuring over 150 summer-themed events, 6,200 premium performances, and 3,800 cultural experience activities [1] - The "Graduation Season in Beijing" initiative includes 10 recommended activities for graduates, with various scenic spots offering free admission and special discounts for high school and college graduates [3] - A total of 10 thematic study tours will be introduced, focusing on red history, traditional arts, and natural exploration, aimed at both domestic and international students [4] Group 2: Performance and Entertainment - The summer performance market will feature 45 youth-oriented shows, 12 art summer camps, and various international performances, including classic plays and children's theater [5] - Notable performances include the comedy "Twelfth Night" and the drama "The Seagull," along with international productions such as Russian plays and Italian musicals [5] Group 3: Tourism and Leisure Activities - The "Summer Rural Tourism Plan" includes seven rural tourism routes, promoting natural exploration and water activities, with free tickets and discounts offered at various scenic spots [6] - Nighttime activities such as night markets, outdoor movies, and music festivals are being organized across different districts to enhance summer leisure experiences [7][8] Group 4: Visitor Experience and Services - The city is focusing on improving visitor experiences by extending opening hours at certain attractions and implementing convenient entry measures for tourists [8] - The "Fly Summer" theme at the Capital Airport includes promotional activities offering discounts on duty-free, dining, and retail [8] Group 5: Safety and Engagement - Tourists are advised to take precautions against heat and ensure safety while traveling, with a call for adherence to public order and tourism etiquette [9] - The tourism bureau encourages visitors to share their experiences on social media platforms, promoting engagement with the "JingcaiSummer" and "BeijingStyle" hashtags [9]
复星医药: 复星医药关于控股子公司药品临床试验进展的公告
Zheng Quan Zhi Xing· 2025-07-09 09:15
Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has initiated a Phase III clinical trial for its self-developed drug, Rumaine (generic name: Luwomeitini tablets), aimed at treating pediatric low-grade glioma in mainland China [1][2]. Drug Information and Research Status - Rumaine is an innovative small molecule chemical drug that acts as a selective inhibitor of MEK1/2 [1]. - As of July 9, 2025, the drug is in Phase III clinical trials for treating pediatric low-grade glioma and is also in Phase II trials for treating extra-cranial arteriovenous malformations and pediatric Langerhans cell histiocytosis in mainland China [2]. - The drug has been included in the breakthrough therapy program by the National Medical Products Administration for two indications: inoperable or residual/recurrent NF1-related plexiform neurofibromas in adult patients and pediatric Langerhans cell histiocytosis [2]. - Cumulative R&D investment in the drug reached approximately RMB 607 million (unaudited) as of May 2025 [2]. - According to IQVIA MIDAS™, global sales of MEK1/2 selective inhibitors are projected to be approximately USD 2.068 billion in 2024 [2].
科前生物:拟与华中农大签订专利实施许可合同、研发及技术许可合同
news flash· 2025-07-09 08:40
科前生物公告,公司拟与华中农大签订专利实施许可合同、研发及技术许可合同。公司就两个研发项目 一共需向华中农大支付335万元人民币。其中,"一株猪δ冠状病毒强毒株及其在疫苗制备中的应用"发明 专利的实施许可支付135万元,"吉氏巴贝斯虫传代致弱活疫苗"的研发及技术许可支付200万元。 ...